江南·(jn·China认证)体育官方网站-JN UEFA Euro 2024

Development History

Yocon Biology Growth Stories

2006Year

Establishment of YOCON

2009Year

Moving to the field of molecular diagnosis

2012Year

Moving to the field of cell therapy

2015Year

Successful R&D of the country's leading medium

2016Year

Adjustment to product R&D strategy

2018Year

Continuous breakthrough

2020Year

Joint response to challenges

2021Year

Launch of a "new star" product

Jul

07Month

  • 2006-07-06

    YOCON Biology was formerly established in a warehouse in Haidian District, Beijing, with 2 members and an area of 35 m2.

May

05Month

  • 2009-05-03

    After recognizing the importance and standardization of national virus sampling, YOCON independently developed virus sampling kits to formally move to the field of molecular diagnosis.

Jun

06Month

  • 2012-06-22

    The company established a serum-free cell culture medium R&D center in Beijing.

Jan

01Month

  • 2015-01-22

    The company completed the successful R&D of the country's leading serum-free medium, which is widely accepted, making the company become a leader in R&D of serum-free cell media in China.

Oct

10Month

  • 2016-10-22

    After successful R&D of serum-free media for NK cells and mesenchymal stem cells, the company began the R&D of automatic cell culture workstation to establish its R&D direction.

Sep

09Month

  • 2018-09-22

    The company has completed the successful R&D of serum-free media for hybridoma cells, CHO cells, HEK293 and other engineered cells, which are available to CDCs, scientific research institutions in universities, industrial enterprises and clinical hospitals.

Jan

01Month

  • 2020-01-22

    After the global outbreak of COVID-19, YOCON virus sampling products, as rare products registered under Class II medical devices in China, were well accepted both at home and abroad. The company has become one of the key government-appointed enterprises for epidemic prevention and control. The company has donated virus sampling products valuing more than RMB 20.00 million, thus making great contributions to domestic and international virus detection.

May

05Month

  • 2021-05-28

    Successful R&D of automatic sample processing and nucleic acid extraction workstation indicates the transformation of YOCON achievements.